Research.Patient.info
Neovascular age-related macular degeneration (NVAMD) research hub
2 indexed studies · 0 currently recruiting
- authorisedPhase II and Phase III (Integrated)
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
This study is looking at a new eye treatment, EYE201, for a serious eye condition called wet age-related macular degeneration (wet AMD). It compares EYE201 to an existing treatment, aflibercept, to see which is better at improving vision over one year.
Spain · Poland · Estonia - authorisedPhase II and Phase III (Integrated)
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
This study is looking at a new eye medicine, EYE201, for a common eye condition called 'wet' age-related macular degeneration (NVAMD). It’s comparing EYE201 to an existing treatment (aflibercept) to see if it’s safe and helps improve or maintain vision.
Austria · Slovakia · Portugal